Sponsored Content by MGIReviewed by Olivia FrostOct 24 2024
Breakthroughs in genomics have transformed the systematic examination of cellular systems throughout human history, improving our understanding of the world and allowing researchers and medical professionals to approach diagnostics and treatment more accurately and objectively than ever.
Image Credit: Piyaset/Shutterstock.com
Researchers have employed and integrated diverse omics data in this pursuit. Combining each “omic” in confluence has achieved more unbiased, comprehensive, and representative insight into the complex molecular mechanisms underpinning biological processes.
MGI’s innovative approach to sequencing combines three powerful technologies: electronic sensors, fluorescence emission, and self-illumination.
These advancements benefit from the flexibility to integrate short-read (DNBSEQ™) and long-read (CyloneSEQ) sequencing, enabling MGI to offer the industry-leading SEQ ALL portfolio.
The SEQ ALL platform provides a wide-ranging, end-to-end solution that accommodates diverse applications, including spatial omics, high-throughput genomics, and single-cell omics.
MGI is currently the only global provider to offer such an expansive, integrated workflow, allowing researchers to benefit from an unmatched combination of scale, versatility, and precision.
The SEQ ALL portfolio facilitates pioneering discoveries across various omics fields, revolutionizing scientists’ approach to exploring and understanding intricate biological systems.
Image Credit: MGI
DNA Omics promises more comprehensive insights into complex diseases
Much discussion has involved the inherent characteristics of long-read and short-read genome sequencing.
Short-read sequencing is suited to the in-depth examination of specific DNA segments. Long-read approaches give researchers a more comprehensive picture of the molecular information under investigation.
Joining both approaches can address individual constraints, enabling a more complete DNA analysis.
MGI’s efficient workflow ensures accurate results through its comprehensive portfolio of clinical ultra-high, high, and medium-throughput sequencers, which are underpinned by the company’s proprietary DNBSEQ technology.
The PCR-free DNBSEQ platform boasts numerous advantages, including high accuracy, low index misalignment, and low duplication rates.
MGI’s capacity to perform large-scale sequencing while maintaining efficiency, stability, data quality, and affordability is widely recognized throughout the sector.
Earlier this year, the company introduced the Standard MPS 2.0 (SM 2.0) upgrade for its DNBSEQ platforms, supplementing its impressive sequencing quality and increasing its percentage of Q40 bases.
MGI has also added the CycloneSEQ long-read technology to its product range. The company can now sequence long strands of DNA/RNA molecules without breaking them into smaller fragments.
Long-read technology offers significant advantages in genomics, transcriptomics, epigenomics, and other fields because it can produce ultra-long read lengths, undertake real-time analysis, and conduct rapid readings.
CycloneSEQ has already demonstrated its potential in various applications, such as human whole-genome de novo assembly, metagenomics sequencing, variant calling, and single-cell RNA sequencing.
It can also accurately and comprehensively detect complex genetic conditions, including thalassemia. It has been successfully applied to generate small animal telomere-to-telomere genome profiles.
Employing both MGI’s short-read and long-read sequencing technologies offers users improved outcomes and more comprehensive genetic testing in diverse research and application settings.
The company’s long-read sequencing technology can produce reads ranging from 10 kb to 1 Mb, compensating for the limited length of short-read technology, whose strength comes from accuracy.
Access to more sequencing options also increases efficiency and cost-effectiveness for customers seeking a one-stop-shop solution that accommodates diverse research requirements.
Multi-omics enables a deeper understanding of biological processes
MGI boasts DNA, cell, and special omics (DCS) options outside its DNA sequencing capabilities, ideally suited to frontier science based on DNBSEQ technologies.
MGI’s cell omics offering includes a complete package suitable for single-cell library preparation and sequencing via a single platform: the DNBelab C series High-Throughput Single-Cell 5’ RNA & V(D)J Library Preparation Kit.
When used with the DNBelab C-TaiM 4 droplet generator, the kit enables efficient droplet encapsulation of cells in just 12 minutes. Alongside the DNBC4Tools analysis software, it can process 20,000 cells per slide per run, enabling single-cell 5’ RNA, TCR, and BCR library preparation while offering robust data quality control analysis.
MGI introduced the innovative FluoXpert technology in April 2024. This technology transforms genome sequencers by incorporating multiplex immunofluorescence capabilities to integrate image-based proteomics detection and sequencing functions within single equipment.
FluoXpert allows researchers to detect more than 20 proteins on one tissue section, affording invaluable insight into applications such as precision medicine and validating high-throughput spatial sequencing.
Many users of MGI’s sequencing equipment in spatial omics have successfully applied the Stereo-seq technology to conduct in-depth research in numerous fields.
Based on DNA Nanoball technology, Stereo-seq is the only spatial technology able to access the entire transcriptome at true single-cell resolution. It can achieve subcellular data via Ultra-HD resolution while offering field-of-view options over 160 cm2.
Researchers also benefit from a powerful tool that allows them to study spatial biology at subcellular resolution and across a broad field of view. It enables simultaneous transcriptome analysis at tissue, cellular, and subcellular levels, whether working with fresh frozen or formalin-fixed paraffin-embedded tissue.
Capturing mRNA on a chip and using spatial barcoding makes in situ sequencing possible, linking gene expression with cell morphology and microenvironments.
The chip comprises billions of DNA NanoBalls and is compatible with MGI’s DNBSEQ sequencing platform, which supports the Stereo-seq system.
MGI launched the DCS Lab Initiative in 2023 to provide end-to-end products for clinical and research applications in DNA genomics, cell omics, and spatial omics. The company has now successfully established 10 international laboratories focused on frontier science.
Image Credit: MGI
SEQ ALL integrates high-throughput DNB sequencing, cell omics, nanopore sequencing, and spatiotemporal genomics, allowing users worldwide to access end-to-end solutions across multi-omics approaches, read lengths, and throughputs.
These features make omics more comprehensive, accurate, and affordable, allowing the public to receive rapid, precise diagnoses and treatments thanks to improved access to genomic testing.
The company’s extensive international network and stable logistics systems underpin MGI’s work to improve efficiency throughout the laboratory process while promoting innovation across the life science industry.
As a global industry leader in tool development, MGI aims to expedite DNA omics, cell omics, and spatiotemporal omics in SEQ ALL to enable pioneering solutions that further enhance life sciences.
Acknowledgments
Produced from materials originally authored by BGI Health (HK) Co., Ltd.
About MGI
MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. MGI focuses on R&D, production and sales of DNA sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, mass spectrometry, medical imaging, and laboratory automation.
Founded in 2016, MGI has more than 2,900 employees, nearly half of whom are R&D personnel. MGI operates in more than 100 countries and regions and has established multiple research and production bases around the world. Providing real-time, comprehensive, life-long solutions, its vision is to enable effective and affordable healthcare solutions for all.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.